|
1
|
Khwaja A, Bjorkholm M, Gale RE, Levine RL,
Jordan CT, Ehninger G, Bloomfield CD, Estey E, Burnett A,
Cornelissen JJ, et al: Acute myeloid leukaemia. Nat Rev Dis
Primers. 2:160102016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Estey E and Döhner H: Acute myeloid
leukaemia. Lancet. 368:1894–1907. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhao H, Shi P, Deng M, Jiang Z, Li Y,
Kannappan V, Wang W, Li P and Xu B: Low dose triptolide reverses
chemoresistance in adult acute lymphoblastic leukemia cells via
reactive oxygen species generation and DNA damage response
disruption. Oncotarget. 7:85515–85528. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zheng HC: The molecular mechanisms of
chemoresistance in cancers. Oncotarget. 8:59950–59964. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tan M, Zhang Q, Yuan X, Chen Y and Wu Y:
Synergistic killing effects of homoharringtonine and arsenic
trioxide on acute myeloid leukemia stem cells and the underlying
mechanisms. J Exp Clin Cancer Res. 38:3082019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lam SS, Ho ES, He BL, Wong WW, Cher CY, Ng
NK, Man CH, Gill H, Cheung AM, Ip HW, et al: Homoharringtonine
(omacetaxine mepesuccinate) as an adjunct for FLT3-ITD acute
myeloid leukemia. Sci Transl Med. 8:359ra1292016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kuroda J, Kamitsuji Y, Kimura S, Ashihara
E, Kawata E, Nakagawa Y, Takeuichi M, Murotani Y, Yokota A, Tanaka
R, et al: Anti-myeloma effect of homoharringtonine with concomitant
targeting of the myeloma-promoting molecules, Mcl-1, XIAP, and
β-catenin. Int J Hematol. 87:507–515. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shi X, Zhu M, Gong Z, Yang T, Yu R, Wang J
and Zhang Y: Homoharringtonine suppresses LoVo cell growth by
inhibiting EphB4 and the PI3K/AKT and MAPK/EKR1/2 signaling
pathways. Food Chem Toxicol. 136:1109602019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Carnero A, Blanco-Aparicio C, Renner O,
Link W and Leal JF: The PTEN/PI3K/AKT signalling pathway in cancer,
therapeutic implications. Curr Cancer Drug Targets. 8:187–198.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Pink RC, Samuel P, Massa D, Caley DP,
Brooks SA and Carter DR: The passenger strand, miR-21-3p, plays a
role in mediating cisplatin resistance in ovarian cancer cells.
Gynecol Oncol. 137:143–151. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Si ML, Zhu S, Wu H, Lu Z, Wu F and Mo YY:
miR-21-mediated tumor growth. Oncogene. 26:2799–2803. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yang SM, Huang C, Li XF, Yu MZ, He Y and
Li J: miR-21 confers cisplatin resistance in gastric cancer cells
by regulating PTEN. Toxicology. 306:162–168. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang J, Yao T, Wang Y, Yu J, Liu Y and
Lin Z: Long noncoding RNA MEG3 is downregulated in cervical cancer
and affects cell proliferation and apoptosis by regulating miR-21.
Cancer Biol Ther. 17:104–113. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lopez MF, Niu P, Wang L, Vogelsang M, Gaur
M, Krastins B, Zhao Y, Smagul A, Nussupbekova A, Akanov AA, et al:
Opposing activities of oncogenic MIR17HG and tumor suppressive
MIR100HG clusters and their gene targets regulate replicative
senescence in human adult stem cells. NPJ Aging Mech Dis. 3:72017.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Xu XM, Qian JC, Deng ZL, Cai Z, Tang T,
Wang P, Zhang KH and Cai JP: Expression of miR-21, miR-31, miR-96
and miR-135b is correlated with the clinical parameters of
colorectal cancer. Oncol Lett. 4:339–345. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liu ZL, Wang H, Liu J and Wang ZX:
MicroRNA-21 (miR-21) expression promotes growth, metastasis, and
chemo- or radioresistance in non-small cell lung cancer cells by
targeting PTEN. Mol Cell Biochem. 372:35–45. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Feng Y, Zou W, Hu C, Li G, Zhou S, He Y,
Ma F, Deng C and Sun L: Modulation of CASC2/miR-21/PTEN pathway
sensitizes cervical cancer to cisplatin. Arch Biochem Biophys
623-624. 20–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zeng B, Ye H, Chen J, Cheng D, Cai C, Chen
G, Chen X, Xin H, Tang C and Zeng J: LncRNA TUG1 sponges miR-145 to
promote cancer progression and regulate glutamine metabolism via
Sirt3/GDH axis. Oncotarget. 8:113650–113661. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Militello G, Weirick T, John D, Döring C,
Dimmeler S and Uchida S: Screening and validation of lncRNAs and
circRNAs as miRNA sponges. Brief Bioinform. 18:780–788.
2017.PubMed/NCBI
|
|
21
|
Paraskevopoulou MD and Hatzigeorgiou AG:
Analyzing miRNA-lncRNA interactions. Methods Mol Biol.
1402:271–286. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wei S, Liu J, Li X and Liu X: LncRNA
MIR17HG inhibits non-small cell lung cancer by upregulating
miR-142-3p to downregulate Bach-1. BMC Pulm Med. 20:782020.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liu H, Zhu C, Xu Z, Wang J, Qian L, Zhou
Q, Shen Z, Zhao W, Xiao W, Chen L and Zhou Y: lncRNA PART1 and
MIR17HG as ΔNp63α direct targets regulate tumor progression of
cervical squamous cell carcinoma. Cancer Sci. 111:4129–4141. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Feng J, Ouyang Y, Xu D, He Q, Liu D, Fan
X, Xu P and Mo Y: Genetic variants in MIR17HG affect the
susceptibility and prognosis of glioma in a Chinese Han population.
BMC Cancer. 20:9762020. View Article : Google Scholar : PubMed/NCBI
|
